The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Zheng, Ruoyi; Chen, Wen-Ming; Xia, Weiting; Zheng, Jingyu; Zhou, Qing

doi:10.1155/2020/7658782

Cited by 13 publications

(19 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the large body of evidence that indicates IGFBP5 acts as a tumor suppressor, there is considerable evidence that it has oncogenic roles. In ovarian cancer, as previously discussed, increased IGFBP5 was positively correlated with decreased overall survival, suggesting it is important for cancer progression (62). In breast cancer, IGFBP5 is oncogenic specifically when it is localized within the nucleus, a phenomenon observed primarily in cell lines engineered to ectopically overexpress IGFBP5 (77).…”

Section: Oncogenic Activity Of Igfbp5mentioning

confidence: 76%

Insulin-like growth factor binding protein 5: Diverse roles in cancer

et al. 2022

View full text Add to dashboard Cite

Insulin-like growth factor binding proteins (IGFBPs) and the associated signaling components in the insulin-like growth factor (IGF) pathway regulate cell differentiation, proliferation, apoptosis, and adhesion. Of the IGFBPs, insulin-like growth factor binding protein 5 (IGFBP5) is the most evolutionarily conserved with a dynamic range of IGF-dependent and -independent functions, and studies on the actions of IGFBP5 in cancer have been somewhat paradoxical. In cancer, the IGFBPs respond to external stimuli to modulate disease progression and therapeutic responsiveness in a context specific manner. This review discusses the different roles of IGF signaling and IGFBP5 in disease with an emphasis on discoveries within the last twenty years, which underscore a need to clarify the IGF-independent actions of IGFBP5, the impact of its subcellular localization, the differential activities of each of the subdomains, and the response to elements of the tumor microenvironment (TME). Additionally, recent advances addressing the role of IGFBP5 in resistance to cancer therapeutics will be discussed. A better understanding of the contexts in which IGFBP5 functions will facilitate the discovery of new mechanisms of cancer progression that may lead to novel therapeutic opportunities

show abstract

Section: Oncogenic Activity Of Igfbp5mentioning

confidence: 76%

Insulin-like growth factor binding protein 5: Diverse roles in cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The subgroup analyses for OC consisted of two studies in our meta-analysis, one of which shows a significant association between IGFBP2 and OC perhaps because of the large sample size gained from GTEx project and TCGA. 36 The other study had only 99 samples and high IGFBP2 expression was not related to prognosis of OC patients. 35 Thus, the sample size may be a reason without statistical significance in OC.…”

Section: Discussionmentioning

confidence: 90%

“…We here used the OR to measure the strength of correlation between IGFBP2 and OC, but a significant connection did not exist in our meta‐analysis. The subgroup analyses for OC consisted of two studies in our meta‐analysis, one of which shows a significant association between IGFBP2 and OC perhaps because of the large sample size gained from GTEx project and TCGA 36 . The other study had only 99 samples and high IGFBP2 expression was not related to prognosis of OC patients 35 .…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of IGFBP2 in various cancers: a systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Background The prognostic significance of insulin‐like growth factor binding protein 2 (IGFBP2) expression has been explored in plenty of studies in human cancers. Because of the controversial results, the meta‐analysis was carried out to evaluate the relevance of IGFBP2 expression with the prognosis in various tumors. Methods The data searched from four databases (Pubmed, Embase, Cochrane library, and Web of science) was used to calculate pooled hazard ratios (HRs) in this meta‐analysis. Subgroup analyses were stratified by ethnicity, cancer type, publication year, Newcastle–Ottawa Scale score, treatments, and populations. Results Twenty‐one studies containing 5560 patients finally met inclusion criteria. IGFBP2 expression was associated with lower overall survival (HR = 1.57, 95% CI = 1.31–1.88) and progression‐free survival (HR = 1.18, 95% CI = 1.04–1.34) in cancer patients, but not with disease‐free survival (HR = 1.50, 95% CI = 0.91–2.46) or recurrence‐free survival (HR = 1.50, 95% CI = 0.93–2.40). The subgroup analyses indicated IGFBP2 overexpression was significantly correlated with overall survival in Asian patients (HR = 1.42, 95% CI = 1.18–1.72), Caucasian patients (HR = 2.20, 95% CI = 1.31–3.70), glioma (HR = 1.36, 95% CI = 1.03–1.79), and colorectal cancer (HR = 2.52, 95% CI = 1.43–4.44) and surgery subgroups (HR = 1.97, 95% CI = 1.50–2.58). Conclusion The meta‐analysis showed that IGFBP2 expression was associated with worse prognosis in several tumors, and may serve as a potential prognostic biomarker in cancer patients.

show abstract

“…The insulin-like growth factor binding protein (IGFBP) family comprises six identified members (IGFBP-1–6) [ 8 ], which are implicated in the pathophysiology process of numerous human diseases, including cancer [ 9 ]. Although the precise mechanism is not completely understood, the IGFBP family plays important roles in lung cancer [ 10 ], ovarian cancer [ 11 ], breast cancer [ 12 ], and obesity [ 13 ]. Using the polymerase chain reaction, GBM cell lines were found to express mRNA for IGFBP genes: IGFBP-1 in 42%, IGFBP-2 in 65%, IGFBP-3 in 97%, IGFBP-4 in 3%, IGFBP-5 in 74%, IGFBP-6 in 94%, and IGFBP-7 in 87% of glioma cell lines [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Analysis of Prognostic Value and Immune Infiltration of IGFBP Family Members in Glioblastoma

Zhong

Han

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. The insulin-like growth factor-binding protein (IGFBP) family is involved in tumorigenesis and the development of multiple cancers. However, little is known about the prognostic value and regulatory mechanisms of IGFBPs in GBM. Oncomine, Gene Expression Profiling Interactive Analysis, PrognoScan, cBioPortal, LinkedOmics, TIMER, and TISIDB were used to analyze the differential expression, prognostic value, genetic alteration, biological function, and immune cell infiltration of IGFBPs in GBM. We observed that IGFBP1, IGFBP2, IGFBP3, IGFBP4, and IGFBP5 mRNA expression was significantly upregulated in patients with GBM, whereas IGFBP6 was downregulated; this difference in mRNA expression was statistically insignificant. Subsequent investigations showed that IGFBP4 and IGFBP6 mRNA levels were significantly associated with overall survival in patients with GBM. Functional Gene Ontology Annotation and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis revealed that genes coexpressed with IGFBP4 and IGFBP6 were mainly enriched in immune-related pathways. These results were validated using the TIMER and TSMIDB databases. This study demonstrated that the IGFBP family has prognostic value in patients with GBM. IGFBP4 and IGFBP6 are two members of the IGFBP family that had the highest prognostic value; thus, they have the potential to serve as survival predictors and immunotherapeutic targets in GBM.

show abstract

The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Cited by 13 publications

References 59 publications

Insulin-like growth factor binding protein 5: Diverse roles in cancer

Insulin-like growth factor binding protein 5: Diverse roles in cancer

Prognostic value of IGFBP2 in various cancers: a systematic review and meta‐analysis

Comprehensive Analysis of Prognostic Value and Immune Infiltration of IGFBP Family Members in Glioblastoma

Contact Info

Product

Resources

About